For research use only.

Catalog No.S8517 Synonyms: Lyxumia, Adlyxin, ZP10A peptide, AVE0010

Lixisenatide Chemical Structure

CAS No. 320367-13-3

Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.

Size Price Stock Quantity  
USD 247 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Glucagon Receptor Inhibitors

Biological Activity

Description Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
GLP-1R [1]
(Cell-free assay)
1.4 nM
In vitro

Lixisenatide protects Ins-1 cells (a rat-derived β-cell line) from both lipid- and cytokine-induced apoptosis. More importantly, Lixisenatide also prevents lipotoxicity-induced insulin depletion in human islets and preserves insulin production, storage and pancreatic β-cell function in vitro. Binding studies in CHO-K1 cells overexpressing the human GLP-1 receptor show that Lixisenatide is a very potent and selective GLP-1 receptor agonist--the binding affinity of Lixisenatide (Ki = 1.33 ± 0.22 nM) is ∼ 4-times greater than that of human GLP-1 (Ki = 5.09 ± 1.19 nM). In more than 80 different binding assays, lixisenatide does not exhibit any relevant interaction with other potential drug targets, confirming its high selectivity for the GLP-1 receptor[3].

In vivo The half-life of lixisenatide is 2-4 hours, and it is classed as a short-acting GLP-1-receptor agonist, compared with the long-acting GLP-1-based peptides, liraglutide and albiglutide. Lixisenatide can significantly improve glucose-stimulated insulin secretion. In healthy normoglycemic dogs, single subcutaneous injections of lixisenatide produces dose-dependent reductions in plasma glucose after an oral glucose challenge and significantly reduces postprandial glucose excursions by 67% compared with placebo without increasing insulin concentrations. The effect of lixisenatide on postprandial blood glucose excursions in dogs is, at least in part, related to inhibition of gastric emptying and delayed intestinal glucose absorption. Dose-dependent reductions in plasma glucose after an oral glucose challenge have also been demonstrated in both the db/db mouse and ZDF rat. Importantly, this activity is glucose-dependent with no effect at physiological glucose concentrations. In db/db mice, chronic lixisenatide administration preventes the progressive deterioration in glucose tolerance observed in control animals and is associated with significant dose-dependent reductions in glycosylated hemoglobin (HbA1c). In ZDF rats, a continuous subcutaneous infusion of lixisenatide 50 μg/kg/day for 12 weeks significantly decreases basal blood glucose and improves oral glucose tolerance compared with control animals. It has no hypoglycemic effect and does not change HbA1c in normoglycemic rats. Lixisenatide can maintain beta cell mass and function through stimulation of islet cell proliferation and neogenesis, and inhibition of islet cell apoptosis[1]. Lixisenatide preserves pancreatic responsiveness in diabetic animals[3].


Animal Research:


- Collapse
  • Animal Models: Male db/db mice C57BLKS/J-Leprdb/Leprdb
  • Dosages: 0.01, 0.1, 1, 10, and 100 nmol/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 100 mg/mL (20.58 mM)
Ethanol '-1 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 4858.49


CAS No. 320367-13-3
Storage powder
in solvent
Synonyms Lyxumia, Adlyxin, ZP10A peptide, AVE0010
Smiles CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(䲧瘆Ỵ瘇㧀瘅膉疴睥ଐ঵ី'঵ð㺣疲帉疲Ѐ瑖猗﫜돸ቬ঵ð鄸ቬ彿猘奋猘巫猘쟜ቬ쫀ቬ彿猘쪴ቬ塚猘쫀ቬꍈ猝돸ቬ學猘漸猝圔猘돸ቬ圞猘圭猘﫜玚Wី' ី'戤睕$๰ઇ䐺疲暼睥๰ઇី' ๰ઇð㺣疲๰ઇ€﫜๴ઇ€䀷疳๴ઇا๴ઇ㵶疳๴ઇ됬ቬ若Item쭄ቬCount﫴歷຤ઇ쫄੟๴ઇ੟씢疳쫈੟㸶䥷猘쟜ቬ쭄ቬ�猝쪴ቬ੟籠﫜猙ӎ﫤礤v�猝쪴ቬ猢W쭄ቬ䨼Ą樓﫤良獸W列𢡄玛W列怠ٙ﫤礤v玚W玢W怠ٙ﫼礌vtЉ

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02274740 Terminated Drug: LIXISENATIDE AVE0010|Drug: metformin Type II Diabetes Mellitus Sanofi April 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Lixisenatide | Lixisenatide ic50 | Lixisenatide price | Lixisenatide cost | Lixisenatide solubility dmso | Lixisenatide purchase | Lixisenatide manufacturer | Lixisenatide research buy | Lixisenatide order | Lixisenatide mouse | Lixisenatide chemical structure | Lixisenatide mw | Lixisenatide molecular weight | Lixisenatide datasheet | Lixisenatide supplier | Lixisenatide in vitro | Lixisenatide cell line | Lixisenatide concentration | Lixisenatide nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID